SWK002
/ Siweikang Pharma, Anhui Provincial Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 28, 2025
Safety and Efficacy of SWK002 in Patients with D2T-Rheumatoid Arthritis
(clinicaltrials.gov)
- P=N/A | N=18 | Recruiting | Sponsor: The First Affiliated Hospital of University of Science and Technology of China | Trial primary completion date: Dec 2024 ➔ Mar 2026
Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
July 16, 2024
Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis
(clinicaltrials.gov)
- P=N/A | N=18 | Recruiting | Sponsor: The First Affiliated Hospital of University of Science and Technology of China
New trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
1 to 2
Of
2
Go to page
1